Mobic Labeling Revision Includes Class Risk Language
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer Ingelheim’s addition of cardiovascular and gastrointestinal risk information to Mobic labeling coincides with FDA approval of a juvenile rheumatoid arthritis indication for meloxicam.
You may also be interested in...
Celebrex Label Adds Cardiovascular Risk Language
Celecoxib labeling revision includes long-term safety data from three celecoxib trials, one of which suggests increased cardiovascular risk. Celebrex also gains ankylosing spondylitis indication.
Celebrex, NSAID Labeling Must Be Updated Within Three Months, FDA Says
FDA's labeling template calls for Pfizer's Celebrex and other prescription NSAIDs to add "black box" warnings on cardiovascular and gastrointestinal risks. FDA is also requiring a warning on skin reactions. The agency issues a medication guide for all NSAIDs.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.